Europe Transthyretin Amyloidosis Treatment Market Size & Outlook

The transthyretin amyloidosis treatment market in Europe is expected to reach a projected revenue of US$ 5,147.6 million by 2030. A compound annual growth rate of 13.9% is expected of Europe transthyretin amyloidosis treatment market from 2025 to 2030.
Revenue, 2024 (US$M)
$2,067.6
Forecast, 2030 (US$M)
$5,147.6
CAGR, 2025 - 2030
13.9%
Report Coverage
Europe

Europe transthyretin amyloidosis treatment market, 2018-2030 (US$M)

Europe

Related Markets

Europe transthyretin amyloidosis treatment market highlights

  • The Europe transthyretin amyloidosis treatment market generated a revenue of USD 2,067.6 million in 2024.
  • The market is expected to grow at a CAGR of 13.9% from 2025 to 2030.
  • In terms of segment, targeted therapy was the largest revenue generating therapy in 2024.
  • Targeted Therapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
  • Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.

Europe data book summary

Market revenue in 2024USD 2,067.6 million
Market revenue in 2030USD 5,147.6 million
Growth rate13.9% (CAGR from 2025 to 2030)
Largest segmentTargeted therapy
Fastest growing segmentTargeted Therapy
Historical data covered2018 - 2023
Base year for estimation2024
Forecast period covered2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationTargeted Therapy, Supportive Therapy
Key market players worldwidePfizer Inc, Johnson & Johnson, Ionis Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Astellas Pharma Inc, Prothena Corp PLC, Acrotech BioPharma, SOM Biotech

Other key industry trends

  • In terms of revenue, Europe region accounted for 31.1% of the global transthyretin amyloidosis treatment market in 2024.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • North America is the fastest growing regional market and is projected to reach USD 8,083.2 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Transthyretin Amyloidosis Treatment Market Scope

Transthyretin amyloidosis treatment market segmentation & scope
Vyndaqel/ Vyndamax
Onpattro
Amvuttra
Tegsedi
Wainua
Supportive Therapy
Pipeline Therapy
ATTR with Polyneuropathy (ATTR-PN)
ATTR with Cardiomyopathy (ATTR-CM)
Polyneuropathy
Cardiomyopathy
Mixed Type
Wild Type Amyloidosis
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies
Online Pharmacies

Transthyretin Amyloidosis Treatment Market Companies

Name Profile # Employees HQ Website

Europe transthyretin amyloidosis treatment market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to transthyretin amyloidosis treatment market will help companies and investors design strategic landscapes.


Targeted therapy was the largest segment with a revenue share of 116.54% in 2024. Horizon Databook has segmented the Europe transthyretin amyloidosis treatment market based on targeted therapy, supportive therapy covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to Europe transthyretin amyloidosis treatment market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe transthyretin amyloidosis treatment market databook

  • Our clientele includes a mix of transthyretin amyloidosis treatment market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe transthyretin amyloidosis treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Europe transthyretin amyloidosis treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Europe transthyretin amyloidosis treatment market size, by country, 2018-2030 (US$M)

Europe Transthyretin Amyloidosis Treatment Market Outlook Share, 2024 & 2030 (US$M)

Europe transthyretin amyloidosis treatment market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more